Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Susan Halabi

Showing results (141-150 of 282) with videos related to

Pageof 29
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline UpdateKenneth Anderson, Nofisat Ismaila, Patrick J Flynn, et al.
JCO Precision Oncology|May 15, 2025
Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) SurveyRhonda L Bitting, Christopher McNair, Alexander W Wyatt, et al.
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.
JCO Precision Oncology|October 31, 2022
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR StudyRanju Gupta, Funda Meric-Bernstam, Michael Rothe, et al.
Pharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
Urology|August 16, 2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary-Ellen Taplin, Daniel J George, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroupJoellen M Schildkraut, Patricia G Moorman, Amy E Bland, et al.
Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.
Pageof 29

Showing results (141-150 of 282) with videos related to

Sort By:
Pageof 29
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2018
Role of Bone-Modifying Agents in Multiple Myeloma: American Society of Clinical Oncology Clinical Practice Guideline UpdateKenneth Anderson, Nofisat Ismaila, Patrick J Flynn, et al.
JCO Precision Oncology|May 15, 2025
Factors Affecting Genomic Testing in Prostate Cancer: Results From the Decision-Making, Experience, and Confidence In Determining Genomic Evaluation (DECIDE) SurveyRhonda L Bitting, Christopher McNair, Alexander W Wyatt, et al.
Journal of the National Cancer Institute|October 19, 2013
Prognostic model predicting metastatic castration-resistant prostate cancer survival in men treated with second-line chemotherapySusan Halabi, Chen-Yen Lin, Eric J Small, et al.
JCO Precision Oncology|October 31, 2022
Pertuzumab Plus Trastuzumab in Patients With Colorectal Cancer With <i>ERBB2</i> Amplification or <i>ERBB2/3</i> Mutations: Results From the TAPUR StudyRanju Gupta, Funda Meric-Bernstam, Michael Rothe, et al.
Pharmaceutical Statistics|November 6, 2020
Estimand framework: Are we asking the right questions? A case study in the solid tumor settingMichelle Casey, Evgeny Degtyarev, María José Lechuga, et al.
Urology|August 16, 2005
Prognostic significance of plasma chromogranin a levels in patients with hormone-refractory prostate cancer treated in Cancer and Leukemia Group B 9480 studyMary-Ellen Taplin, Daniel J George, Susan Halabi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 7, 2010
Phase III trial of bevacizumab plus interferon alfa versus interferon alfa monotherapy in patients with metastatic renal cell carcinoma: final results of CALGB 90206Brian I Rini, Susan Halabi, Jonathan E Rosenberg, et al.
Cancer Epidemiology, Biomarkers & Prevention : a Publication of the American Association for Cancer Research, Cosponsored by the American Society of Preventive Oncology|March 20, 2008
Cyclin E overexpression in epithelial ovarian cancer characterizes an etiologic subgroupJoellen M Schildkraut, Patricia G Moorman, Amy E Bland, et al.
Journal of the National Cancer Institute|September 27, 2015
The Development of Intermediate Clinical Endpoints in Cancer of the Prostate (ICECaP), Christopher Sweeney, Mari Nakabayashi, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 16, 2003
Androgen receptor mutations in androgen-independent prostate cancer: Cancer and Leukemia Group B Study 9663Mary-Ellen Taplin, Barur Rajeshkumar, Susan Halabi, et al.
Pageof 29